Literature DB >> 8707757

Therapy-related myeloid leukemia.

M J Thirman1, R A Larson.   

Abstract

One of the most serious possible consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can be distinguished currently. These include classic therapy-related myeloid leukemia, leukemia that follows treatment with agents that inhibit topoisomerase II, acute lymphoblastic leukemia, and leukemias with 21q22 rearrangements or inv(16) or t(15;17). These types of leukemia are discussed in detail in this article.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8707757     DOI： 10.1016/s0889-8588(05)70340-3

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  23 in total

Review 1.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.

Authors:  C Lavau; R T Luo; C Du; M J Thirman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.

Authors:  Zhijian Qian; Anthony A Fernald; Lucy A Godley; Richard A Larson; Michelle M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

4.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

Authors:  N Zhao; A Stoffel; P W Wang; J D Eisenbart; R Espinosa; R A Larson; M M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.

Authors:  Satoshi Nishiwaki; Seitaro Terakura; Takahiko Yasuda; Nobuhiko Imahashi; Hiroshi Sao; Hiroatsu Iida; Yoshikazu Kamiya; Keiko Niimi; Yoshihisa Morishita; Akio Kohno; Toshiya Yokozawa; Haruhiko Ohashi; Masashi Sawa; Yoshihisa Kodera; Koichi Miyamura
Journal:  Int J Hematol       Date:  2010-02-10       Impact factor: 2.490

6.  Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer.

Authors:  J Arends; C Unger
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

7.  Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.

Authors:  Michael Zach Koontz; Sandra J Horning; Raymond Balise; Peter L Greenberg; Saul A Rosenberg; Richard T Hoppe; Ranjana H Advani
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

8.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.

Authors:  Jeffrey A Knight; Andrew D Skol; Abhijit Shinde; Darcie Hastings; Richard A Walgren; Jin Shao; Thelma R Tennant; Mekhala Banerjee; James M Allan; Michelle M Le Beau; Richard A Larson; Timothy A Graubert; Nancy J Cox; Kenan Onel
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 9.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

10.  MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.

Authors:  Nathan A Ellis; Dezheng Huo; Ozlem Yildiz; Lisa J Worrillow; Mekhala Banerjee; Michelle M Le Beau; Richard A Larson; James M Allan; Kenan Onel
Journal:  Blood       Date:  2008-04-21       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.